and separase mutants were created using kits from Stratagene (ExSite) or Promega (GeneEditor).
CDC6 ORF and downstream sequence was PCR amplified (CGGGATCCATGTCAGCTATACCAATAACTCCAACTAAG & GGGAAACTATATGCAATATAACACGTAAACC) from genomic S. cerevisiae DNA and
BamH1/Nhe1-cloned into pRS425/BamH1/Spe1. Into the resulting vector PCR amplified (CTATCTATTGTTGGGCGAAACCTAGAG & CGGGATCCTATATGGTACTATTGATGAAAATAGTGCAGCG) CDC6 promoter was integrated via Xho1/BamH1 to give pOS391. GST-fusion constructs were created by integration of annealed oligos into pGEX-4T-1/BamH1/Xho1. For expression of Cdc6 mutants in yeast BamH1/Pst1 fragments from these plasmids were subcloned into pOS391.
Mass Spectroscopy and Sequence Alignments
Proteins were digested in-gel with trypsin, analyzed by MALDI-TOF (Bruker, Reflex III) as described (Shevchenko et al., 1996) and identified by matching peptide mass values against MSDB database using MASCOT peptide fingerprint search engine. The EMBOSS algorithm (method: water, matrix: Blosum40, gap penalty: 15, extend penalty: 0.5) was used to align the separase peptide PQAPRVQQRVQTRLKVNFSDDS with a linear concatenation of the following CKIs: INK4b, INK4a, INK4c, INK4d, CIP1, KIP1, KIP2, p107, p130 (all human), dacapo, roughex, S. c. Cdc6, Sic1, and Rum1. Full-length S. c. Cdc6 and human separase were aligned using the same parameters.
Recombinant Protein
Baculoviruses were produced following Invitrogen's instructions for the Bac-to-Bac System. SF-9 cells co-infected with Cdk1 (WT or KD), 2xHis 6 -Tev 2 -∆90 and Cks2 viruses were lysed in 50 mM Tris/HCl pH 8.0, 300 mM NaCl, 5 mM β-mercaptoethanol, 0.5 % NP40, 5 mM NaF, 5 mM β-glycerophosphate, 15 mM imidazole, 1 µM microcystin-LR and complete protease inhibitor cocktail (Roche). Ni 2+ -NTA (Qiagen) was incubated with a 100,000 x g extract, washed and eluted with 250 imidazole. Cdk1 was dialyzed against 30 mM Tris/HCl 8.5, 80 mM NaCl, 3 mM DTT, fractionated on MonoQ (0.1 ml), and again dialyzed against 30 mM Hepes/KOH pH 7.7, 30% glycerol, 80 mM KCl, 1 mM DTT to 15.5 ng/µl. Overexpression in human cells was by transfection of 293T with pCS2 plasmids and production of human His 6 -∆90 and securin were described before (Stemmann et al., 2001 ). His-tagged Xenopus securin∆90 was prepared like human securin. Bacterially expressed cyclin B1∆90 was purified according to instructions for the pMAL System (NEB) and eluted at a concentration of 12 µg/µl in Cdk1 storage buffer containing 30 mM maltose. GST fusion constructs were purified from bacteria as recommended by
Amersham and stored in CSF-XB, 10 mM DTT at 4°C. Concentration of highly pure recombinant ∆90 was determined by Lowry and OD 280 and used as a standard for quantitative Western.
Antibodies and IPs from Human Cells
Antibodies against human securin and the N-terminus (all Western blots) and an internal fragment (S1305 to T1573; IPs in Figure 2 ) of human separase were described (Stemmann et al., 2001; Zou et al., 1999) . Rabbit anti-Cks antibody was raised against the peptide HYMIHEPEPHILLFRRPLPK (Bethyl). Other antibodies and affinity matrices were as follows:
human Cdk1 -Santa Cruz-54; human cyclin B1 -Upstate 05-373 ( Figure ( Figure 2C , right) was affinity purified on Ni 2+ -NTA (10 µl) in the same buffer but with 6 mM imidazole and 500 mM NaCl and eluted with 250 mM imidazole.
Xenopus Extracts and Inhibition Experiments
CSF-XB buffer, Xenopus CSF extracts, and sperm nuclei were prepared according to (Murray, 1991) . Degradation of securin from ZZ-Tev 4 -separase-securin complexes by incubation in Xenopus low (55 nM) or high (550 nM) ∆90 extracts, cleavage and degradation assays using 35 Slabeled human Scc1 or securin, respectively, and histone H1 phosphorylation assay were described previously (Stemmann et al., 2001) . In Cdk1 elution experiments 10 µl of separase beads (approximately 5 µg) were re-isolated from ∆90 extracts and washed with CSF-XB, 0.01% Triton X100, 200 mM NaCl (unless specified other) or incubated in 30 µl of CSF-XB with 15 µg of human securin or 60 µg of histone H1 (Sigma). Beads were then washed twice with CSF-XB, 0.01% Triton X100 and once with 10 mM Hepes/KOH pH 7.7, 50 mM NaCl, 25 mM NaF, 1 mM EGTA, 20% glycerol before separase was eluted by incubation with Tev-protease. Cohesin cleavage was quantified by phospho-imager (BAS-2500, Fuji) and the amount of ∆90 was determined by Western using a CCD camera (LAS-1000) and Image Gauge software (both Fuji).
Binding of Cdk1 to WT and mutant Cdc6 N-terminus was assayed by incubating 30 µg GST fusion protein bound to 10 µl beads in 0.1 ml low ∆90 extract, washing with CSF-XB, 0.01% Tween 20, 300 mM NaCl, 10 mM DTT and eluting with SDS. For mitotic exit experiments cycloheximide (0.1 mg/ml), rhodamine-tubulin (30 ng/µl, Cytoskeleton), sperm (10 3 /µl), and ∆90
(55 nM) supplemented extract was released with Ca 2+ (0.6 mM) for 20 minutes before separasesecurin complexes (42 nM) were added. Alternatively, cycloheximide, rhodamine-tubulin, and sperm containing extract was combined with Xenopus securin∆90 (0.75 mg/ml) 30 minutes prior to release. For reconstitution of separase inhibition with purified components, 2 µl of Tev-eluted separase re-isolated from ∆90 Xenopus extracts (about 10 ng) were incubated with 11 µl of Cdk1 or ∆90 (various dilutions) in 30 mM Hepes/KOH pH 7.7, 30% glycerol, 80 mM KCl, 1 mM DTT, 30 mg/ml BSA for 15 minutes at room temperature before 2 µl of 35 S-Scc1 were added.
Unphosphorylated WT separase was obtained by incubating 2 µl purified separase (about 10 ng) with 1 µl λ-PPase (0,5 mg/ml, NEB) or reference buffer thereof for 30 minutes at room temperature before 50 ng of KD or WT Cdk1 and ATP/Mg 2+ (1 mM) were added. After additional 20 minutes at room temperature separase activity was assayed.
For inhibition of Cdk1 with free separase, 10 µl of either WT or PM separase (about 50 ng) or reference buffer were combined with 1 µl Cdk1 (0,6 ng/µl) and incubated for 20 min at room temperature, before assaying kinase activity. 
